Drugs / DRL_RI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02296775 | Nov 2014 → Nov 2016 | rheumatoid arthritis | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT03976102 | May 2019 → Sep 2022 | follicular lymphoma | Dr. Reddy's Laboratories Limited | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DRL_RI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03976102 ↗ |
| Known as | rituximab | “DRL_RI, a proposed rituximab biosimilar” PMID 32052313 ↗ Apr 2020 |
| Route | Intravenous | “administered via IV infusion” NCT03976102 ↗ |